156017-44-6

Upstream product

• 156017-41-3 [Difluoro-(4-iodo-phenyl)-methyl]-phosphonic acid diethyl ester 
• 156017-42-4 2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-iodo-propionic acid methyl ester 
• 113850-77-4 (S)-methyl 2-amino-3-(4-iodophenyl)propanoate 
• 1991-81-7 4-iodo-L-phenylalanine 
• 63-91-2 L-phenylalanine 
• 1711-02-0 4-iodobenzoic acid chloride 
• 229962-91-8 methyl (2S)-2-(((9H-fluoren-9-ylmethoxy)carbonyl)amino)-3-(((4-methylbenzene)sulfonyl)oxy)propanoate 
• 156017-40-2 diethyl (4-iodobenzoyl)phosphonate 
• 82911-78-2 N-[(9-fluorenylmethoxy)carbonyl]-L-serine methyl ester 
• 82565-68-2 N-fmoc-4-iodo-(L)-phenylalanine 
• 65094-22-6 diethyl (bromodifluoromethyl)phosphonate 
• 195258-67-4 (S)-methyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-iodophenyl)propanoate 

Downstream Products

• 932725-90-1 C₄₇H₅₉Cl₂F₄N₇O₁₅P₂ 
• 880596-78-1 C₃₅H₃₅ClF₂N₃O₉P 
• 880596-94-1 C₃₅H₃₆ClF₂N₄O₈P 
• 880595-63-1 C₃₆H₃₇ClF₂N₃O₉P 
• 880595-07-3 C₃₁H₃₃Cl₂F₂N₂O₅P 
• 156017-45-7 (S)-2-{[(9H-fluoren-9-yl)methoxy]carbonylamino}-3-{4-[(diethoxyphosphoryl)difluoromethyl]phenyl}propanoic acid 

Relevant academic research and scientific papers

Enantioselective synthesis of N-Boc and N-Fmoc protected diethyl 4-phosphono(difluoromethyl)-L-phenylalanine; agents suitable for the solid-phase synthesis of peptides containing nonhydrolyzable analogues of O-phosphotyrosine

Enantioselective convergent syntheses of N-Boc and N-Fmoc protected diethyl 4-phosphono(difluoromethyl)-L-phenylalanine are reported.

An Intrinsic Hydrophobicity Scale for Amino Acids and Its Application to Fluorinated Compounds

More than 100 hydrophobicity scales have been introduced, with each being based on a distinct condensed-phase approach. However, a comparison of the hydrophobicity values gained from different techniques, and their relative ranking, is not straightforward

PENTAFLUOROPHOSPHATE DERIVATIVE, ITS USES AND AN APPROPRIATE MANUFACTURING METHOD

The invention relates to a pentafluorophosphate derivative according to general formula (I): or a pharmaceutically acceptable salt or solvate thereof. Thereby, R1 and R2 denote independently from each other H or F; R3 denotes H, an optionally substituted C1-C10 alkyl, an optionally substituted C3-C10 cycloalkyl, or an optionally substituted C6-C20 aryl, wherein a hydrocarbon chain of the alkyl, the cycloalkyl or the aryl can be interrupted by one or more oxygen, sulfur and/or nitrogen atoms; and M denotes any cation; with the proviso that at least one of R1 and R2 denotes F, if R3 denotes H. The invention further relates to uses of such a pentafluorophosphate derivative and to an appropriate manufacturing method.

Synthesis and cell-based activity of a potent and selective protein tyrosine phosphatase 1B inhibitor prodrug

Our laboratory recently reported the development of novel prodrug chemistry for the intracellular delivery of phosphotyrosine mimetics. This chemistry has now been adapted for the synthesis of a prodrug that delivers the nonhydrolyzable difluoromethylphos

PRODRUGS OF DRUG-PHOSPHATE CONJUGATES AND ANALOGS THEREOF

Phosphate-substituted therapeutic compounds and analogs thereof that may serve as prodrugs are described. The prodrugs may include phosphorus-containing compounds, drug-phosphate conjugates, and analogs of drug-phosphate conjugates. Also described are ana

A facile solution and solid phase synthesis of phosphotyrosine mimetic L-4-[diethylphosphono(difluoromethyl)]-phenylalanine (F2Pmp(EtO)2) derivatives

The F2Pmp derivatives were prepared in 80-90% yield from commercially available protected L-4-iodophenylalanine by esterification with diazomethane followed by a CuCl-mediated coupling to (diethylphosphonyl) difluoromethylcadmium bromide. Moreover, treatment of L-4-iodoPhe-containing peptides under the same coupling conditions provided the F2Pmp-containing peptides in very good yields.